Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-04T19:16:50.652Z Has data issue: false hasContentIssue false
  • English
  • Français

Evaluating and improving the quality of risperidone prescribing

Published online by Cambridge University Press:  02 January 2018

David Taylor ,
Robert Holmes ,
Trudi Hilton  and
Carol Paton
David Taylor*
Affiliation:
Bethlem and Maudsley NHS Trust, London SE5 8AZ
Robert Holmes
Affiliation:
Royal London Hospital (Mile End), Bancroft Road, London E1 4DG
Trudi Hilton
Affiliation:
Ealing Hospital Uxbridge Road, Middlesex UB1 3HW
Carol Paton
Affiliation:
Bexley Hospital Old Bexley Lane, Bexley DA5 2BW
*
∗Correspondence
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Clinical studies suggest that risperidone is an effective antipsychotic with a low incidence of extrapyramidal adverse effects. In a prescription survey of several trusts, we found that risperidone was widely prescribed at high doses alongside typical neuroleptics and anticholinergic drugs. We also demonstrated that prescribing in a single trust can be improved by simple interventions. Risperidone should be prescribed as the sole antipsychotic at doses below 8 mg/day to realise fully its clinical advantages. Few prescriptions met this standard.

Type
Original Papers
Information
Psychiatric Bulletin , Volume 21 , Issue 11 , November 1997 , pp. 680 - 683
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1997 The Royal College of Psychiatrists

References

Avnon, M. & Kunin, A. (1995) Risperidone response after no clozapine response (letter). British Journal of Psychiatry. 167, 699.CrossRefGoogle Scholar
Borison, R. L., Pathiraja, A. P., Diamond, B. I., et al (1992) Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin, 28, 213–218.Google ScholarPubMed
Carpenter, W. T., Conley, R. R., Buchanan, R. W., et al (1995) Patient response and resource management: another view of clozapine treatment of schizophrenia. American Journal of Psychiatry, 152, 827–832.Google ScholarPubMed
Chaplin, R. & McGuigan, S. (1996) Antipsychotic dose: from research to clinical practice. Psychiatric Bulletin, 20, 452–454.CrossRefGoogle Scholar
Chouinard, G., Jones, B., Remington, G., et al (1993). A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13, 25–40.CrossRefGoogle ScholarPubMed
Claus, A., Bollen, J., De Cuyper, H., et al (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenia in-patients: a multicentre double-blind comparative study. Acta Psychiatrica Scandinavica, 85, 295–305.CrossRefGoogle Scholar
Kane, J. M., Honingfeld, G., Singer, J., et al (1988) Clozapine for the treatment of resistant schizophrenia. Archives of General Psychiatry, 45, 789–796.CrossRefGoogle Scholar
Keck, P. E., Cohen, B. M., Baldessarine, R. J., et al (1989) Time course of antipsychotic effect of neuroleptic drugs. American Journal of Psychiatry, 146, 1289–1292.Google ScholarPubMed
Keck, P. E., Wilson, D. R., Strakowski, S. M., et al (1995) Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. Journal of Clinical Psychiatry, 56, 466–470.Google ScholarPubMed
Livingston, M. G. (1994) Drug profile – risperidone. Lancet, 343, 457–460.CrossRefGoogle Scholar
Marder, S. R. & Meibach, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825–835.Google ScholarPubMed
Mok, H. & Yatham, L. N. (1994) Response to clozapine as a predictor of risperidone response in schizophrenia. American Journal of Psychiatry, 151, 1393–1394.Google ScholarPubMed
Peuskens, J. (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national. multi-centre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry, 166, 712–726.CrossRefGoogle ScholarPubMed
Thompson, C. (1994) The use of high-dose antipsychotic medication. British Journal of Psychiatry, 164, 448–458.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.